Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
Walgreens Boots Alliance, Inc. (WBA) is the first global pharmacy-led, health and wellbeing enterprise. Formed in December 2014 through the combination of Walgreens and Alliance Boots, the company harnesses the strengths of two iconic brands with complementary geographic footprints and a heritage that dates back over a century. WBA operates over 13,100 stores in 11 countries and has a presence in more than 25 countries, employing over 370,000 people worldwide.
WBA is the largest retail pharmacy, health, and daily living destination in the USA and Europe, with its extensive network ensuring nearly three-quarters of Americans live within five miles of a Walgreens location. The company's revenue is majorly generated from prescription drug sales, which account for about two-thirds of its overall sales. Walgreens alone contributes to 20% of total prescription revenue in the U.S.
Alongside prescription sales, WBA's operations include retail products, European drug wholesale, and healthcare services. The company is continuously expanding its services with initiatives such as Health Corner and Village Medical, aiming to create an omnichannel experience for patients and positioning itself as a one-stop healthcare provider.
In recent developments, WBA has made significant strides towards sustainability, such as reducing single-use plastic in its packaging and collaborating with industry partners for better recycling practices. The efforts are part of the company's broader Environmental, Social, and Governance (ESG) initiatives aimed at reducing its environmental impact.
Additionally, Walgreens is expanding its specialty pharmacy services through the introduction of Walgreens Specialty Pharmacy, which integrates AllianceRx and focuses on providing care for patients with complex, chronic conditions. This initiative aims to improve patient outcomes and provide greater value to payers and partners.
WBA’s specialty pharmacy business is bolstered by its subsidiary, Shields Health Solutions, which supports health systems' specialty pharmacies across the U.S. Through these efforts, Walgreens continues to play a pivotal role in the healthcare system, offering comprehensive solutions that bridge gaps in patient care.
For National Women's Health Month, Walgreens has been highlighting the contributions of its female leaders, emphasizing the importance of women's health and wellness. The company organized events focused on work-life balance, mental health, and leadership development, furthering its commitment to diversity, equity, and inclusion.
With a mission to provide joy through better health, Walgreens Boots Alliance remains a trusted name in the healthcare and retail pharmacy sectors, continuously evolving to meet the needs of its customers and communities worldwide.
Walgreens Boots Alliance (Nasdaq: WBA) will host its virtual annual stockholders' meeting on Jan. 28, 2021, at 8:00 a.m. CST, accessible via their investor relations website. A live audio webcast will be available, with a replay archived for 12 months. Executive Chairman Jim Skinner and CEO Stefano Pessina will present, followed by a Q&A session for attendees. WBA, a global leader in pharmacy and healthcare, operates over 21,000 stores in more than 25 countries, focusing on community health and sustainability.
No7 announces the launch of its latest product, Laboratories Resurfacing Peel 15% Glycolic Acid, aimed at providing an at-home alternative to professional dermatological treatments. The peel utilizes glycolic acid, known for its exfoliating properties, along with gluconolactone for improved efficacy and skin tolerance. Dermatologist Dr. Tess Mauricio endorses the product, noting visible improvements in skin texture and tone after usage. The peel retails for $39.99 and is available online.
Walgreens has issued a statement in response to President-elect Biden’s COVID-19 Update, expressing support for his plan to boost vaccine distribution through pharmacies. Walgreens cites its extensive network and experience, stating it is well-positioned to administer COVID-19 vaccines across the nation. The company has been vaccinating vulnerable populations in long-term care facilities since December and is ready to broaden its vaccine efforts in local communities. Walgreens aims to provide convenient and equitable access to vaccines for all Americans.
OFP Real Estate, LLC has acquired a net-leased investment property tenanted by Walgreens Boots Alliance (WBA) in the Cleveland, Ohio metro area. This acquisition, which marks OFP's first for 2021, was secured with a long-term lease, ensuring stable and predictable returns. The purchase increases OFP's net-lease investments to over $45,000,000 across five states, with aims to exceed a $150,000,000 acquisition target by year-end. The firm focuses on income-producing investments from leading retail tenants.
Walgreens is enhancing its financial services by partnering with Synchrony and Mastercard to launch credit and prepaid debit cards. These offerings will integrate with the myWalgreens loyalty program, providing customers with cash rewards and additional benefits at over 9,000 Walgreens locations and beyond. The cards aim to boost customer engagement and create new revenue streams, with features like contactless payments and health-focused rewards. The new financial products are expected to be available in the second half of this year, reflecting Walgreens' commitment to improving health and wellness payment solutions.
Walgreens Boots Alliance (Nasdaq: WBA) has announced a majority investment in iA, a provider of software-enabled automation solutions for the pharmacy sector. This strategic investment aims to enhance iA's pharmacy automation offerings, thus streamlining medication dispensing and enabling pharmacists to focus more on patient care. The move aligns with the growing demand for efficient healthcare solutions, especially post-COVID-19, aiming to modernize pharmacy operations and improve patient outcomes.
Walgreens Boots Alliance (WBA) reported first-quarter fiscal 2021 results, with sales of $36.3 billion, a 5.7% increase from the prior year. Despite strong sales, the company faced an operating loss of $440 million, largely due to a $1.5 billion equity charge from AmerisourceBergen. Net loss was $308 million, with adjusted EPS down 11.2% to $1.22. The company maintains its fiscal 2021 guidance for low single-digit growth in adjusted earnings per share. Walgreens continues its critical role in COVID-19 vaccinations, with over 2.8 million tests administered.
Walgreens Boots Alliance (Nasdaq: WBA) has significantly increased its investment in VillageMD to establish 600 to 700 Village Medical at Walgreens clinics across more than 30 U.S. markets over the next four years. This initiative builds on previous plans, with WBA completing a $750 million investment as part of a larger $1 billion commitment. The clinics aim to provide accessible, coordinated healthcare, particularly in underserved areas, emphasizing the integration of pharmacists into primary care teams for enhanced patient support.
Walgreens aims to complete COVID-19 vaccine first doses for skilled nursing facilities by January 25. The company is expanding vaccine access to assisted living facilities and other vulnerable groups. Since receiving vaccines in December, Walgreens has efficiently vaccinated populations across 49 states and Puerto Rico, administering to over 35,000 long-term care facilities. Planning is underway for broader vaccine distribution to essential workers and seniors aged 75 and older in over 9,000 stores. Walgreens is committed to health equity, focusing on underserved communities impacted by COVID-19.
AmerisourceBergen (ABC) will acquire Walgreens Boots Alliance's (WBA) Alliance Healthcare for $6.5 billion, comprising $6.275 billion in cash and 2 million shares. This acquisition enhances AmerisourceBergen's global distribution capabilities and allows WBA to focus on its retail pharmacy expansion. The deal is projected to create annual run-rate synergies of at least $150 million by the fourth year. Additionally, the U.S. distribution agreement is extended to 2029, aiming for greater efficiencies. AmerisourceBergen expects a high-teens percentage accretion to adjusted EPS in the first fiscal year after closing.